SLS SELLAS Life Sciences Group, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1390478 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-37.8%
TTM EPS YoY28.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-40.3%
ROA-37.1%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets6.6%
Debt / equity0.00x
Current ratio14.92x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.76x
Accruals ratio-8.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q3*2026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q3*2025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $0 | — | — | — | $0 | — | — | — |
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | $0 | — | — | — | $0 | — | — | — |
| R&D expense | $7.03M | $6.27M | $5.13M | $4.73M | $4.22M | $3.87M | $3.21M | $4.44M |
| SG&A expense | $4.28M | $4.36M | $4.12M | $3.52M | $2.87M | $3.00M | $2.86M | $2.48M |
| Operating income | -$11.31M | -$10.63M | -$9.25M | -$8.26M | -$7.08M | -$6.87M | -$6.06M | -$6.92M |
| Net income | -$10.09M | -$9.61M | -$8.41M | -$7.66M | -$6.79M | -$6.60M | -$5.81M | -$6.74M |
| EPS (basic) | -0.05 | -0.05 | -0.05 | — | -0.06 | -0.07 | -0.07 | — |
| EPS (diluted) | -0.05 | -0.05 | -0.05 | — | -0.06 | -0.07 | -0.07 | — |
| Weighted avg. shares (diluted) | 202.44M | 189.18M | 172.48M | — | 108.40M | 98.56M | 87.76M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $134.71M | $138.34M | $107.10M | $71.79M | $44.42M | $25.40M | $28.50M | $13.99M |
| Current assets | $138.57M | $142.50M | $111.17M | $75.21M | $49.05M | $29.45M | $31.97M | $16.33M |
| Goodwill | $1.91M | $1.91M | $1.91M | $1.91M | $1.91M | $1.91M | $1.91M | $1.91M |
| Total assets | $141.09M | $145.38M | $114.18M | $78.34M | $51.55M | $32.30M | $34.96M | $19.43M |
| Current liabilities | $9.29M | $7.57M | $6.46M | $7.02M | $5.92M | $6.00M | $6.89M | $9.51M |
| Total liabilities | $9.29M | $7.73M | $6.76M | $7.47M | $5.92M | $6.16M | $7.20M | $9.97M |
| Shareholders' equity | $131.81M | $137.66M | $107.41M | $70.87M | $45.63M | $26.15M | $27.76M | $9.46M |
| Shares outstanding | 203.53M | 201.92M | 181.33M | 153.10M | 125.08M | 100.37M | 90.90M | 73.98M |
| Cash flow statement | ||||||||
| Operating cash flow | -$5.94M | -$7.59M | -$8.85M | -$4.92M | -$7.07M | -$7.33M | -$9.07M | -$7.15M |
| Investing cash flow | — | — | — | — | — | — | — | $0 |
| Financing cash flow | $2.31M | $38.83M | $44.15M | $32.39M | $26.09M | $4.23M | $23.58M | $8,000 |
| Stock-based compensation | $1.93M | $1.01M | $798,000 | $447,000 | $503,000 | $501,000 | $505,000 | $373,000 |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.